AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTERIS TECHNOLOGIES LTD

5.180

+0.3807.92%

Volume:7.83K

Turnover:39.09K

Market Cap:186.80M

PE:-1.02

High:5.180

Open:4.850

Low:4.850

Close:4.800

Loading ...

Overview Company News Filings

Two ASX healthcare shares that could be set to double

Anteris Technologies Widens Loss in Q1 as Sales Fall

MT Newswires Live

Press Release: Anteris Announces Results for the First Quarter of 2025

ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium

The Sydney Morning Herald

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%

MT Newswires Live

Anteris Technologies Reports Positive One-Year Results for Patients Treated with Transcatheter Heart Valve System

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays

Anteris Technologies Receives Australian Taxation Office Class Rulings

MT Newswires Live

Anteris Technologies' IPO Underwriters' Representatives Partially Exercise Over-Allotment Option; Shares Up 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","market":"AU","secType":"STK","nameCN":"ANTERIS TECHNOLOGIES LTD","latestPrice":5.18,"timestamp":1752819120000,"preClose":4.8,"halted":0,"volume":7832,"delay":0,"nameEN":"ANTERIS TECHNOLOGIES LTD","floatShares":27691457,"shares":36062370,"eps":-5.073495574065051,"marketStatus":"Market Closed","change":0.38,"latestTime":"07-18 16:12:00 AEST","open":4.85,"high":5.18,"low":4.85,"amount":39090,"amplitude":0.06875,"askPrice":5.19,"askSize":5000,"bidPrice":4.9,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-5.073495574065051,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":4.8,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":0.29054540457725675,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","floatShares":27691457,"roa":"-135.31%","roe":"-263.65%","lyrEps":-5.789933,"volumeRatio":0.29054540457725675,"shares":36062370,"dividePrice":0,"high":5.18,"amplitude":0.06875,"preClose":4.8,"low":4.85,"week52Low":4.26,"pbRate":"2.81","psRate":"48.75","week52High":17.05,"institutionHeld":0,"latestPrice":5.18,"committee":-0.666667,"eps":-5.073495574065051,"divideRate":0,"volume":7832,"delay":0,"ttmEps":-5.073495574065051,"open":4.85,"prevYearClose":8.27,"prevWeekClose":5.29,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5.29,"twentyDayClose":6.03,"sixtyDayClose":5.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550622802","title":"Two ASX healthcare shares that could be set to double","url":"https://stock-news.laohu8.com/highlight/detail?id=2550622802","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550622802?lang=en_us&edition=fundamental","pubTime":"2025-07-10 06:49","pubTimestamp":1752101380,"startTime":"0","endTime":"0","summary":"The ASX healthcare sector has largely been flat in the last year compared to sectors like tech and financials. However, broker Bell Potter sees upside in two ASX healthcare shares that have fallen con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/07/10/two-asx-healthcare-shares-that-could-be-set-to-double/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","CU6.AU","AVR.AU","BK7126","BK7096"],"gpt_icon":0},{"id":"2535603496","title":"Anteris Technologies Widens Loss in Q1 as Sales Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2535603496","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535603496?lang=en_us&edition=fundamental","pubTime":"2025-05-14 07:51","pubTimestamp":1747180302,"startTime":"0","endTime":"0","summary":"Anteris Technologies  reported Wednesday a loss after income tax of $21.9 million in the first quarter, 36% wider than its loss of $16.2 million a year ago, according to a Wednesday Australian bourse filing.The company's research and development expenses climbed 42% to $16.5 million from $11.6 million last year as it upscaled its manufacturing capabilities, the filing said.Net sales for the three months ended March 31 fell 27% to $600,000 from $800,000 in the year-ago period, reflecting lower demand for tissue products.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR.AU"],"gpt_icon":0},{"id":"2535334060","title":"Press Release: Anteris Announces Results for the First Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535334060","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535334060?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:45","pubTimestamp":1747172700,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS and BRISBANE, Australia, May 13, 2025  -- Anteris Technologies Global Corp.   a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update.-- Investigational Device Exemption  for the DurAVR THV's global,pivotal clinical trial , submitted to the FDA. -- Scale up for commencement of the PARADIGM Trial ongoing -- including. expanding the Clinical Specialist Team and contracting with planned. -- Clinical milestone of 100 patients successfully treated with the. DurAVR THV -- comprised of de novo aortic stenosis cases including. The proposed DurAVR THV global pivotal registration trial has been formally designated as the PARADIGM Trial, signifying the trial's central role in the DurAVR THV Clinical Development Program.An IDE application for the PARADIGM Trial was submitted to the U.S. F","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4022","BK4232","BK7007","BK7126","AVR.AU","AVR","R"],"gpt_icon":0},{"id":"2529620992","title":"ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium","url":"https://stock-news.laohu8.com/highlight/detail?id=2529620992","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529620992?lang=en_us&edition=fundamental","pubTime":"2025-04-24 16:04","pubTimestamp":1745481840,"startTime":"0","endTime":"0","summary":"On a short week, the markets saw a nice post-Easter bump with the ASX finishing up 2.5 per cent across three days, primarily thanks to another volatile Trump tariff backflip - this time with China.After weeks of escalating China-United States trade war tensions, US President Donald Trump announced plans to cut the unprecedented 140 per cent tariffs placed on China, perhaps understanding his game of chicken with the largest export nation in the world might not turn out to be as rosy as he had hoped.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/asx-runners-of-the-week-redstone-resources-anteris-and-jindalee-lithium-20250424-p5lu34.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["BK4104","AVR.AU","PLS.AU","JLL.AU","BK4567","BK4588","IE00B5TLWC47.USD","FAST","BK7007","BK4585","IE00BFXG0V08.USD","BK7095","BK7511","BK7504","IE00BYQQ9H92.USD","BK7507","BHP.AU","RDS.AU","BK7126"],"gpt_icon":0},{"id":"2523910613","title":"Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV","url":"https://stock-news.laohu8.com/highlight/detail?id=2523910613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523910613?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:15","pubTimestamp":1743419700,"startTime":"0","endTime":"0","summary":"MINNEAPOLISand BRISBANE, Australia, March 31, 2025  -- Anteris Technologies Global Corp.   a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR Transcatheter Heart Valve  has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis.Over 100 patients successfully treated with the DurAVR THV, including de novo  aortic stenosis cases, valve-in-valve  patients and complex anatomies such as bicuspid aortic valve patients*. Dr. Michael Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor of Cardiothoracic Surgery at the Houston Methodist Hospital and Study Chair of the DurAVR THV Pivotal Trial said, “We are building on a strong foundation of clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anteris-technologies-reaches-clinical-milestone-111500161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVR","BK4082","AVR.AU"],"gpt_icon":0},{"id":"2523314249","title":"Anteris Technologies Says Over 100 Patients Treated with Aortic Stenosis Medical Device; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523314249","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523314249?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:22","pubTimestamp":1743384148,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said its biomimetic DurAVR transcatheter heart valve  has been used to treat over 100 patients worldwide, according to a Monday filing with the Australian bourse.Among the patients, 65 completed the primary endpoint measures of safety and efficacy, the filing said.The company plans to begin the DurAVR THV pivotal trial in the third quarter of the year, awaiting US Food and Drug Administration approval, per the filing.Shares were down 6% in morning trade on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","AVR.AU","BK7007"],"gpt_icon":0},{"id":"2521411656","title":"Anteris Technologies Reports Positive One-Year Results for Patients Treated with Transcatheter Heart Valve System","url":"https://stock-news.laohu8.com/highlight/detail?id=2521411656","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521411656?lang=en_us&edition=fundamental","pubTime":"2025-03-21 08:53","pubTimestamp":1742518392,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said that one-year results for patients treated with its proprietary, balloon expandable, DurAVR Transcatheter Heart Valve system showed sustained \"excellent\" effective orifice area, low mean gradients, and zero prosthesis-patient mismatch small annuli patients, according to a Friday Australian bourse filing.The DurAVR THV demonstrated a favorable hemodynamic profile sustained to one-year. No valve or cardiovascular-related mortality was reported.Current commercial devices demonstrated prosthesis-patient mismatch rates of between 11.2% to 35.3%, a predictor of valve failure and disease progression.The one-year data builds on the existing clinical evidence and will be included in the planned Investigational Device Exemption submission to the US Food and Drug Administration to seek approval to conduct a DurAVR THV randomized, global pivotal study.A total of 65 patients completed the primary endpoint measure at 30 days.Its shares slid 2% in early trading on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7126","AVR.AU"],"gpt_icon":0},{"id":"2520845848","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2520845848","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520845848?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:42","pubTimestamp":1742470946,"startTime":"0","endTime":"0","summary":"OptiNose (OPTN) shares soared 58% pre-bell Thursday after the company said overnight it agreed to a $330 million takeover by Paratek Pharmaceuticals.ProAssurance (PRA) shares surged 49% after the comp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR","BK4107","AVR.AU","PRA","BK4082","BK7007","BK4007","OPTN","BK7126"],"gpt_icon":0},{"id":"2514288329","title":"Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2514288329","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514288329?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025  -- Anteris Technologies Global Corp.   a structural heart company developing DurAVRTHV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference.The details of each conference and how to access them are as follows:. Fireside chat with analyst, Joshua Jennings, and 1x1 meetings. Anteris’ lead product, the DurAVR Transcatheter Heart Valve , was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood fl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anteris-present-healthcare-investor-conferences-130000956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4207","TD","BK4082","BK7126","BK4585","COWN","BK4566","BK4137","HCSG","AVR.AU","AVR","BK4127","BK7007"],"gpt_icon":0},{"id":"2511469502","title":"Anteris Technologies Receives Australian Taxation Office Class Rulings","url":"https://stock-news.laohu8.com/highlight/detail?id=2511469502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511469502?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:41","pubTimestamp":1739490110,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global  said that the Australian Taxation Office  has issued three class rulings related to the company, according to a Thursday filing with the Australian bourse.The rulings cover shareholders, employee, director options, and investor options and confirm the availability of rollover relief for eligible parties under relevant Australian capital gains tax laws, following the implementation of Anteris' schemes of arrangement, the filing said.Price : $12.85, Change: $-0.19, Percent Change: -1.46%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","XKO.AU","LU0994945656.USD","XAO.AU","BK4588","LU0426417589.USD","LU1043141123.HKD","LU2238339852.HKD","AUD","XJO.AU","LU0426412945.USD","BK4197","ATO","LU0345774631.USD","AVR.AU","BK4585","BK7007","BK4125"],"gpt_icon":0},{"id":"2503465835","title":"Anteris Technologies' IPO Underwriters' Representatives Partially Exercise Over-Allotment Option; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503465835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503465835?lang=en_us&edition=fundamental","pubTime":"2025-01-15 09:51","pubTimestamp":1736905886,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said the representatives of the underwriters of its US initial public offering partially exercised the over-allotment option for 78,481 common shares at $6 apiece, less underwriting discounts and commissions of $0.42 per share, according to a Wednesday filing with the Australian bourse.The representatives are TD Cowen, Barclays, and Cantor. The portion of the over-allotment option that was not exercised lapsed on Jan. 11. Settlement occurred on Jan. 14.Separately, TD Cowen ceased its market stabilization activities on Jan. 12. During the stabilization period, TD Cowen purchased over 2.1 million common shares for prices ranging from $5.14 to $6 on the Nasdaq market.Anteris Technologies' shares were up more than 3% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR.AU","BK7126","BK7007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-12-11","symbol":"AVR.AU","reason":null,"defaultRemindTime":1733871600000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1733835600000},{"market":"AU","date":"2024-10-15","symbol":"AVR.AU","reason":null,"defaultRemindTime":1728946800000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1728910800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVR.AU\",market:\"AU\",,,undefined,":[]}}